Brainard Capital Management’s Amgen AMGN Stock Holding History

Brainard Capital Management’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-842	Closed	-$221K	–	101
2022 Q4	$221K	Buy	+842	New	+$226K	0.19%	83

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Brainard Capital Management's AMGN Position: Q1 2023 in Review

Brainard Capital Management sold out of Amgen (AMGN) in Q1 2023, closing a stake of 842 shares — an estimated $221K sold.

Brainard Capital Management first reported a position in AMGN in Q4 2022 and held it in 1 quarter. The position peaked at $221K in Q4 2022. 2,435 funds tracked by Wall St. Rank hold AMGN as of Q1 2023.

Brainard Capital Management reported no remaining Amgen position as of Q1 2023 after selling out during the quarter.
Brainard Capital Management sold 842 Amgen shares in Q1 2023, an estimated $221K.
Brainard Capital Management first reported a position in Amgen in Q4 2022 and held it in 1 quarter.
Brainard Capital Management's Amgen position peaked at $221K in Q4 2022.
2,435 funds tracked by Wall St. Rank held Amgen as of Q1 2023.

Based on Brainard Capital Management's 13F filing for Q1 2023, filed 9 May 2023.